Analyzing the correlation between CYP1B1 gene polymorphism and efficacy can provide important basis for the design of personalized treatment plans for NSCLC patients, thereby improving treatment effectiveness and reducing side effects. The gene discussed is CYP1B1; the disease is non-small cell lung carcinoma.